Cargando…
Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma
BACKGROUND/AIMS: This study aimed to investigate whether everolimus (EVR) affects long-term survival after liver transplantation (LT) in patients with hepatocellular carcinoma (HCC). METHODS: The data from 303 consecutive patients with HCC who had undergone LT from January 2012 to July 2018 were ret...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association for the Study of the Liver
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524068/ https://www.ncbi.nlm.nih.gov/pubmed/34293849 http://dx.doi.org/10.3350/cmh.2021.0038 |
_version_ | 1784585433188925440 |
---|---|
author | Kang, Incheon Lee, Jae Geun Choi, Sung Hoon Kim, Hyun Jeong Han, Dai Hoon Choi, Gi Hong Kim, Myoung Soo Choi, Jin Sub Kim, Soon Il Joo, Dong Jin |
author_facet | Kang, Incheon Lee, Jae Geun Choi, Sung Hoon Kim, Hyun Jeong Han, Dai Hoon Choi, Gi Hong Kim, Myoung Soo Choi, Jin Sub Kim, Soon Il Joo, Dong Jin |
author_sort | Kang, Incheon |
collection | PubMed |
description | BACKGROUND/AIMS: This study aimed to investigate whether everolimus (EVR) affects long-term survival after liver transplantation (LT) in patients with hepatocellular carcinoma (HCC). METHODS: The data from 303 consecutive patients with HCC who had undergone LT from January 2012 to July 2018 were retrospectively reviewed. The patients were divided into two groups: 1) patients treated with EVR in combination with calcineurin inhibitors (CNIs) (EVR group; n=114) and 2) patients treated with CNI-based therapy without EVR (non-EVR group; n=189). Time to recurrence (TTR) and overall survival (OS) after propensity score (PS) matching were compared between the groups, and prognostic factors for TTR and OS were evaluated. RESULTS: The EVR group exhibited more aggressive tumor biology than the non-EVR group, such as a higher number of tumors (P=0.003), a higher prevalence of microscopic vascular invasion (P=0.017) and exceeding Milan criteria (P=0.029). Compared with the PS-matched non-EVR group, the PS-matched EVR group had significantly better TTR (P<0.001) and OS (P<0.001). In multivariable analysis, EVR was identified as an independent prognostic factor for TTR (hazard ratio [HR], 0.248; P=0.001) and OS (HR, 0.145; P<0.001). CONCLUSIONS: Combined with CNIs, EVR has the potential to prolong long-term survival in patients undergoing LT for HCC. These findings warrant further investigation in a well-designed prospective study. |
format | Online Article Text |
id | pubmed-8524068 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Korean Association for the Study of the Liver |
record_format | MEDLINE/PubMed |
spelling | pubmed-85240682021-10-29 Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma Kang, Incheon Lee, Jae Geun Choi, Sung Hoon Kim, Hyun Jeong Han, Dai Hoon Choi, Gi Hong Kim, Myoung Soo Choi, Jin Sub Kim, Soon Il Joo, Dong Jin Clin Mol Hepatol Original Article BACKGROUND/AIMS: This study aimed to investigate whether everolimus (EVR) affects long-term survival after liver transplantation (LT) in patients with hepatocellular carcinoma (HCC). METHODS: The data from 303 consecutive patients with HCC who had undergone LT from January 2012 to July 2018 were retrospectively reviewed. The patients were divided into two groups: 1) patients treated with EVR in combination with calcineurin inhibitors (CNIs) (EVR group; n=114) and 2) patients treated with CNI-based therapy without EVR (non-EVR group; n=189). Time to recurrence (TTR) and overall survival (OS) after propensity score (PS) matching were compared between the groups, and prognostic factors for TTR and OS were evaluated. RESULTS: The EVR group exhibited more aggressive tumor biology than the non-EVR group, such as a higher number of tumors (P=0.003), a higher prevalence of microscopic vascular invasion (P=0.017) and exceeding Milan criteria (P=0.029). Compared with the PS-matched non-EVR group, the PS-matched EVR group had significantly better TTR (P<0.001) and OS (P<0.001). In multivariable analysis, EVR was identified as an independent prognostic factor for TTR (hazard ratio [HR], 0.248; P=0.001) and OS (HR, 0.145; P<0.001). CONCLUSIONS: Combined with CNIs, EVR has the potential to prolong long-term survival in patients undergoing LT for HCC. These findings warrant further investigation in a well-designed prospective study. The Korean Association for the Study of the Liver 2021-10 2021-07-23 /pmc/articles/PMC8524068/ /pubmed/34293849 http://dx.doi.org/10.3350/cmh.2021.0038 Text en Copyright © 2021 by The Korean Association for the Study of the Liver https://creativecommons.org/licenses/by-nc/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kang, Incheon Lee, Jae Geun Choi, Sung Hoon Kim, Hyun Jeong Han, Dai Hoon Choi, Gi Hong Kim, Myoung Soo Choi, Jin Sub Kim, Soon Il Joo, Dong Jin Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma |
title | Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma |
title_full | Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma |
title_fullStr | Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma |
title_full_unstemmed | Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma |
title_short | Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma |
title_sort | impact of everolimus on survival after liver transplantation for hepatocellular carcinoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524068/ https://www.ncbi.nlm.nih.gov/pubmed/34293849 http://dx.doi.org/10.3350/cmh.2021.0038 |
work_keys_str_mv | AT kangincheon impactofeverolimusonsurvivalafterlivertransplantationforhepatocellularcarcinoma AT leejaegeun impactofeverolimusonsurvivalafterlivertransplantationforhepatocellularcarcinoma AT choisunghoon impactofeverolimusonsurvivalafterlivertransplantationforhepatocellularcarcinoma AT kimhyunjeong impactofeverolimusonsurvivalafterlivertransplantationforhepatocellularcarcinoma AT handaihoon impactofeverolimusonsurvivalafterlivertransplantationforhepatocellularcarcinoma AT choigihong impactofeverolimusonsurvivalafterlivertransplantationforhepatocellularcarcinoma AT kimmyoungsoo impactofeverolimusonsurvivalafterlivertransplantationforhepatocellularcarcinoma AT choijinsub impactofeverolimusonsurvivalafterlivertransplantationforhepatocellularcarcinoma AT kimsoonil impactofeverolimusonsurvivalafterlivertransplantationforhepatocellularcarcinoma AT joodongjin impactofeverolimusonsurvivalafterlivertransplantationforhepatocellularcarcinoma |